drugset / Trial / NCT02400775

A Study to Evaluate the Effects of Azilsartan on Coronary Artery Plaque in Essential Hypertensive Patients With Stable Angina and Dyslipidemia.

NCT02400775

Phase 4 Withdrawn Takeda
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effects of oral azilsartan once daily for 32 weeks on coronary artery plaque in essential hypertensive patients with stable angina and dyslipidemia.

Timeline

Start
2015-03
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Azilsartan Unknown 20 mg Oral

Indications

No indication recorded.